ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)

ClinicalTrials.gov ID: NCT00795639

Public ClinicalTrials.gov record NCT00795639. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 7:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Safety And Efficacy Study Of Sitaxsentan Sodium In Subjects With Pulmonary Arterial Hypertension

Study identification

NCT ID
NCT00795639
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
183 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • Sitaxsentan Drug

Drug

Eligibility (public fields only)

Age range
16 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2008
Primary completion
Feb 28, 2011
Completion
Feb 28, 2011
Last update posted
Mar 23, 2015

2008 – 2011

United States locations

U.S. sites
32
U.S. states
18
U.S. cities
31
Facility City State ZIP Site status
Pfizer Investigational Site Fountain Valley California 92708
Pfizer Investigational Site Mather California 95655
Pfizer Investigational Site Sacramento California 95817
Pfizer Investigational Site Englewood Colorado 80113
Pfizer Investigational Site Littleton Colorado 80120
Pfizer Investigational Site Gainesville Florida 32610
Pfizer Investigational Site Sarasota Florida 34233
Pfizer Investigational Site Weston Florida 33331
Pfizer Investigational Site Chicago Illinois 60612
Pfizer Investigational Site Olathe Kansas 66061
Pfizer Investigational Site Towson Maryland 21204
Pfizer Investigational Site Boston Massachusetts 02111
Pfizer Investigational Site Omaha Nebraska 68131
Pfizer Investigational Site New Brunswick New Jersey 08903
Pfizer Investigational Site Islandia New York 11749
Pfizer Investigational Site Stony Brook New York 11794
Pfizer Investigational Site Chapel Hill North Carolina 27599
Pfizer Investigational Site Cincinnati Ohio 45219
Pfizer Investigational Site Cleveland Ohio 44106
Pfizer Investigational Site Lancaster Pennsylvania 17602
Pfizer Investigational Site Lancaster Pennsylvania 17603
Pfizer Investigational Site Philadelphia Pennsylvania 19140
Pfizer Investigational Site Pittsburgh Pennsylvania 15212
Pfizer Investigational Site Providence Rhode Island 02903
Pfizer Investigational Site Charleston South Carolina 29425
Pfizer Investigational Site Dallas Texas 75390
Pfizer Investigational Site Houston Texas 77030
Pfizer Investigational Site San Antonio Texas 78229
Pfizer Investigational Site Temple Texas 76508
Pfizer Investigational Site Lynchburg Virginia 24501
Pfizer Investigational Site Richmond Virginia 23225
Pfizer Investigational Site Milwaukee Wisconsin 53215

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00795639, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 23, 2015 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00795639 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →